{"schema":"sb.node.v1","id":"sb:e/7e334b5071e5b4486106b1fd","kind":"entity","label":{"text":"kras","locale":"en"},"identity":{"anchor":"label:en:kras","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-06T17:33:03.396507+00:00","snapshot":"deploy eacaa690824dbd9b264c4fb1dc30ea9919aeb0e2"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":415,"separatePublishers":167,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-01-01","to":"2026-10-05","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.137: about 86% of mentions carry no typed assertion"]}},"dimensions":{"domains":["oncology","pubmed_targeted"],"activeDays":163,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/641bef6899a171526bf969cf","kind":"observation","label":"J Thromb Haemost · 2026-10-03 · KRAS Mutation and Venous Thromboembolism Risk in Colorectal Cancer: A Danish Population-Based Cohort Study.","url":"https://doi.org/10.1016/j.jtha.2026.09.040"},{"id":"sb:o/d2e7022309f8e2b8a74daf48","kind":"observation","label":"KRAS Mutation Research (Google News) via Google News · 2026-10-02 · Understanding the KRAS Mutation Landscape in Biliary Tract Cancer - CancerNetwork","url":""},{"id":"sb:o/a73f08a3aeb44fe4d85d37a9","kind":"observation","label":"Int J Cancer · 2026-10-02 · Spatial Transcriptomic Profiling Reveals a Fibroblast-Associated Extracellular Matrix Niche in KRAS G12C-Mutant Lung Adenocarcinoma Primary Tumors From Patients With Metas…","url":"https://doi.org/10.1002/ijc.70764"},{"id":"sb:o/2d826aa152f0d0c7a6af75d0","kind":"observation","label":"Fierce Pharma · 2026-10-02 · Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS","url":"https://www.fiercepharma.com/pharma/astrazeneca-2b-bet-ivonescimab-novo-buys-hengrui-glp-1-merck-doubles-down-kras"},{"id":"sb:o/d2e7022309f8e2b8a74daf48","kind":"observation","label":"KRAS Mutation Research (Google News) via Google News · 2026-10-02 · FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC - OncLive","url":""},{"id":"sb:o/35413ecea0896642063aa0a1","kind":"observation","label":"Future Oncol · 2026-10-01 · SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.","url":"https://doi.org/10.1080/14796694.2026.2736401"},{"id":"sb:o/6a931cb2c80562aff8124c0c","kind":"observation","label":"GEN - Genetic Engineering & Biotechnology News · 2026-09-30 · Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue","url":"https://www.genengnews.com/topics/cancer/merck-scibrunch-launch-up-to-2-13b-collaboration-to-develop-preclinical-kras-inhibiting-molecular-glue/"},{"id":"sb:o/b09e6115e404bda93b4e7aab","kind":"observation","label":"Sci Transl Med · 2026-09-30 · FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer.","url":"https://doi.org/10.1126/scitranslmed.aea4608"},{"id":"sb:o/3368fe705730c6b5ba31802d","kind":"observation","label":"Endpoints News · 2026-09-29 · Merck licenses a KRAS G12D inhibitor for $400M upfront","url":"https://endpoints.news/merck-licenses-a-kras-g12d-inhibitor-for-400m-upfront/"},{"id":"sb:o/d2e7022309f8e2b8a74daf48","kind":"observation","label":"Targeted Therapy Oncology (Google News) via Google News · 2026-09-29 · Are KRAS Mutations More Common Than We Think? - Targeted Oncology","url":""}],"cursor":"c1.eyJpZCI6InNiOmUvN2UzMzRiNTA3MWU1YjQ0ODYxMDZiMWZkIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA2VDE3OjMzOjAzLjM5NjUwNyswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":11,"byKind":{"claim":1,"co-mentioned":10},"items":[{"id":"sb:p/dc4a7cfeab7e30fa39397026","kind":"claim","label":"FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer. — single source","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with colorectal cancer (135 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a2b974f1c240c095cd3e4442"},{"kind":"relation","label":"co-mentioned with lung cancer (78 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1715d936aa939769f1c32a6b"},{"kind":"relation","label":"co-mentioned with pancreatic cancer (60 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/83d1c9a39c2982651db49395"},{"kind":"relation","label":"co-mentioned with kras-mutant (50 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/01eda8a71d27fc6bc646c93f"},{"kind":"relation","label":"co-mentioned with fda (44 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f319f74e915cd587acf7358a"},{"kind":"relation","label":"co-mentioned with immunotherapy (43 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2ad88300301226428172cfc9"},{"kind":"relation","label":"co-mentioned with egfr (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e48ba47d5ab3e22994704e75"},{"kind":"relation","label":"co-mentioned with braf (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/abaa7c6a30c041e79af1c7de"},{"kind":"relation","label":"co-mentioned with pdac (23 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/804a650e8d5ad2ceb6fb5fd8"}],"cursor":"c1.eyJpZCI6InNiOmUvN2UzMzRiNTA3MWU1YjQ0ODYxMDZiMWZkIiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0wNlQxNzozMzowMy4zOTY1MDcrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/7e334b5071e5b4486106b1fd","mcp":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\"}","page":"/entity/kras/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}